Login / Signup

Dose-Response of Paraxanthine on Cognitive Function: A Double Blind, Placebo Controlled, Crossover Trial.

Dante XingChoongsung YooDrew GonzalezVictoria JenkinsKay NottinghamBroderick DickersonMegan LeonardJoungbo KoMark FariesWesley KephartMartin PurpuraRalf JägerShawn D WellsRyan SowinskiChristopher J RasmussenRichard B Kreider
Published in: Nutrients (2021)
PXN may serve as an effective nootropic agent at doses as low as 50 mg.
Keyphrases
  • placebo controlled
  • phase iii
  • phase ii
  • double blind
  • study protocol
  • open label
  • clinical trial
  • phase ii study
  • randomized controlled trial